# Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Source: https://onco.cc/trials/nct05688280/  
OnCo record `nct05688280` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of 1.0% IP-001 for Injection in colorectal cancer, non-small-cell lung cancer and sarcomas, run by Immunophotonics, Inc., active and no longer recruiting.

## Summary

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS is a phase 1/2 interventional study registered as NCT05688280 by Immunophotonics, Inc., with 42 participants enrolled, started 2022-11-29 and due to reach its primary completion in 2025-02. Interventions recorded: 1.0% IP-001 for Injection.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05688280
- Phase: 1/2
- Setting: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients
- Sponsor: Immunophotonics, Inc.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT05688280: https://clinicaltrials.gov/study/NCT05688280

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05688280.json